Coronary heart disease combined with hypertension and vascular dysfunction Circulatory System
Conditions
Interventions
We will recruit 68 patients with hypertension and coronary artery disease who had been admitted to The First Affiliated Hospital, Sun Yat-Sen University. Patients will be randomly divided into XKS gro
Sponsors
Shandong Wohua Pharmaceutical Co Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years 2. Diagnosed with hypertension and coronary artery disease and have received regular coronary heart disease secondary prevention drugs and antihypertensive drugs 3. Baseline GAD-7 and PHQ-9 score were both between 5-14 points 4. Have given written informed consent prior to study participation
Exclusion criteria
Exclusion criteria: 1. Severe liver or kidney dysfunction or malignant tumors 2. Allergic to any component of Xinkeshu tablet 3. Cardiovascular or cerebrovascular accident within previous 3 months 4. Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Brachial arterial flow-mediated dilation measured using ultrasound at baseline, 4 weeks and 12 weeks 2. Brachial-ankle pulse wave velocity measured using a blood pressure measuring device at baseline, 4 weeks and 12 weeks 3. Anxiety assessed using the GAD-7 questionnaire at baseline, 4 weeks and 12 weeks 4. Depression assessed using the PHQ-9 questionnaire at baseline, 4 weeks and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Endothelial microparticles measured using flow cytometry of peripheral blood samples taken at baseline, 4 weeks and 12 weeks 2. Quantity of endothelial progenitor cells measured using flow cytometry of peripheral blood samples taken at baseline, 4 weeks and 12 weeks 3. Blood pressure measured using a tronic sphygmomanometer (HEM-7071, OMRON, China) at baseline, 4 weeks and 12 weeks | — |
Countries
China
Contacts
Public ContactJiapan Sun
Outcome results
None listed